Voyager Therapeutics Inc (VYGR) — Cash Flow-to-Debt Ratio
Voyager Therapeutics Inc (VYGR) has a Cash Flow-to-Debt Ratio of -0.45x as of September 2025, meaning its operating cash flow of $-31.05 Million could theoretically repay 0% of its total liabilities ($68.49 Million) in one year. Explore Voyager Therapeutics Inc (VYGR) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Voyager Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Voyager Therapeutics Inc across 12 annual periods. Also explore balance sheet size of Voyager Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Voyager Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Voyager Therapeutics Inc. For market capitalisation and broader financial context, see Voyager Therapeutics Inc (VYGR) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.16x | $-15.31 Million | $93.29 Million | ▼ -124.2% |
| 2023 | 0.68x | $77.92 Million | $114.96 Million | ▲ +643.7% |
| 2022 | -0.12x | $-12.51 Million | $100.34 Million | ▲ +77.0% |
| 2021 | -0.54x | $-53.52 Million | $98.80 Million | ▲ +39.9% |
| 2020 | -0.90x | $-96.72 Million | $107.26 Million | ▼ -572.9% |
| 2019 | 0.19x | $48.67 Million | $255.25 Million | ▲ +256.7% |
| 2018 | -0.12x | $-15.89 Million | $130.58 Million | ▲ +90.0% |
| 2017 | -1.22x | $-61.35 Million | $50.43 Million | ▼ -53.6% |
| 2016 | -0.79x | $-42.48 Million | $53.64 Million | ▼ -215.8% |
| 2015 | 0.68x | $41.30 Million | $60.38 Million | ▲ +159.4% |
| 2014 | -1.15x | $-11.92 Million | $10.35 Million | ▲ +15.9% |
| 2013 | -1.37x | $-5.45 Million | $3.98 Million | — |